Providing complex support in analytics and bioanalytics of large molecules, a BioPharma department’s capabilities help get more efficient drugs to patients and subsequently improve quality of life.

An essential part of QUINTA-ANALYTICA’s service portfolio, its BioPharma team offers comprehensive support via the testing of large, more complex pharmaceutical products such as peptides, proteins, monoclonal antibodies, and antibody-drug conjugates.

Led by Milan Madera, who has a strong background in characterization using chromatographic and mass spectrometric techniques, the dept. is equipped with modern high resolution/high mass accuracy LC-MS/MS, capillary electrophoresis designed for biopharma applications, and ELISA readers with a state-of-the-art MSD electrochemiluminescence platform which allows for immunogenicity testing of therapeutic drugs.

Despite being the newest dept. of Quinta, its operation in R&D, GMP, GLP, and GCP regimes help clients through the development and validations of methods not only for routine analysis of therapeutic products but also as bioanalytical support for preclinical and clinical testing.

If you’re looking for characterization of complex analytes or their quantification in various biological matrices, get in touch with Milan or the rest of the team today.

Additional News

  • 18 July 2023

    Challenges of a large-scale study of breast cancer

    Our bioanalytical experts and a high-profile client team up for the development of a new therapy for breast cancer.

  • 29 June 2023

    EU funding for Quinta-Analytica laboratory in Brno (CZ) was succesfully completed.

    After two years, the project to finance new equipment for the Quinta-Analytica laboratory in Brno was successfully completed. The investment from European Regional Development Fund was used in this project.

  • 22 June 2023

    Quinta Analytica Partners with EvidentIQ to Enhance Efficiency of Phase 1 Studies

    EvidentIQ partners with Quinta-Analytica to enhance Phase 1 study efficiency